Claims
- 1. A compound 8 to 50 nucleobases in length targeted to a 5′-untranslated region, a start codon region, nucleobases 149 through 354, nucleobases 409 through 452, nucleobases 455 through 536, nucleobases 605 through 684, nucleobases 735 through 870, nucleobases 943 through 981, nucleobases 1002 through 1318 of a coding region, a stop codon region, or a 3′-untranslated region of a nucleic acid molecule encoding RECQL5 of SEQ ID NO: 3, wherein said compound specifically hybridizes with one of said regions and inhibits the expression of RECQL5.
- 2. The compound of claim 1 which is an antisense oligonucleotide.
- 3. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
- 4. The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.
- 5. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
- 6. The compound of claim 5 wherein the modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.
- 7. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
- 8. The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine.
- 9. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
- 10. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
- 11. The composition of claim 10 further comprising a colloidal dispersion system.
- 12. The composition of claim 10 wherein the antisense compound is an antisense oligonucleotide.
- 13. A method of inhibiting the expression of RECQL5 of SEQ ID NO: 3 in cells or tissues comprising contacting said cells or tissues in vitro with the antisense compound of claim 1 so that expression of RECQL5 is inhibited.
- 14. A compound up to 50 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO: 15, 16, 17, 20, 22, 24, 25, 26, 27, 28, 29, 30, 31, 38, 39, 41, 42, 43, 47, 48, 50, 51, 52, 53, 54, 57, 58, 59, 60, 61, 62, 63, 64, 65, 69, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 or 92 which inhibits the expression of RECQL5 of SEQ ID NO: 3.
- 15. The compound of claim 14 which is an antisense oligonucleotide.
- 16. The compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
- 17. The compound of claim 16 wherein the modified internucleoside linkage is a phosphorothioate linkage.
- 18. The compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
- 19. The compound of claim 18 wherein the modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.
- 20. The compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
- 21. The compound of claim 20 wherein the modified nucleobase is a 5-methylcytosine.
- 22. The compound of claim 15 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
- 23. A composition comprising the compound of claim 14 and a pharmaceutically acceptable carrier or diluent.
- 24. The composition of claim 23 further comprising a colloidal dispersion system.
- 25. The composition of claim 23 wherein the antisense compound is an antisense oligonucleotide.
- 26. A method of inhibiting the expression of RECQL5 of SEQ ID NO: 3 in cells or tissues comprising contacting said cells or tissues in vitro with the antisense compound of claim 14 so that expression of RECQL5 is inhibited.
- 27. A compound comprising SEQ ID NO: 26, 47 or 39.
Parent Case Info
[0001] This application is a continuation of U.S. Ser. No. 09/798,185 filed Mar. 1, 2001.
Continuations (1)
|
Number |
Date |
Country |
Parent |
09798185 |
Mar 2001 |
US |
Child |
10309362 |
Dec 2002 |
US |